Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet
NCT00747929
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
724
Enrollment
INDUSTRY
Sponsor class
Conditions
Obesity
Interventions
DRUG:
S-2367 Placebo
DRUG:
S-2367 800 mg
DRUG:
S-2367 1600 mg
OTHER:
Reduced Calorie Diet
Sponsor
Shionogi